Sepsis Diagnostics Markets 2027–2031

Sepsis Diagnostics Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027–2031

Global forecasts by technology, clinical use, infection source, care setting and product, for 14 countries and regions, with 38 company profiles.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

Sepsis diagnostics is a market built on an old, slow method, the blood culture, and on a simple clinical fact: every hour of delay in effective antibiotics costs lives. The market grows from $1,290 million in 2026 to $2,100 million in 2031, at 10.2% a year. Blood culture remains the largest technology, but faster answers take the growth: direct-from-blood tests, rapid susceptibility testing and host-response tests grow from $296.6 million to $714.0 million, more than half of the $810 million of new spending.

Market Size 2026: USD $1.29B Market Size 2031: USD $2.1B CAGR: 10.2%

Situation Analysis: what is really happening

• Payment now follows outcomes. SEP-1 counts in Medicare's Hospital Value-Based Purchasing payments from October 2025, and the FY2027 hospital rule adds a sepsis readmission measure with penalties from FY2030.
• The guidelines got stricter. The 2026 Surviving Sepsis Campaign guidelines suggest procalcitonin for stopping antibiotics, not for starting them, and found insufficient evidence for new host-response tests.
• Blood culture has a new owner. Waters completed its combination with BD's diagnostics business, taking over BACTEC and Phoenix, and won FDA clearance for the BACTEC FXI system.
• Rapid susceptibility is the growth engine. Rapid AST grows 17.6% a year, from $135.4 million to $304.5 million; Bruker bought the former Accelerate Diagnostics assets and Q-linea expanded its ASTar menu.
• Direct-from-blood testing grows fastest. It rises 22.4% a year, from $103.2 million to $283.5 million, despite the wind-down of T2 Biosystems; Karius is now orderable through Mayo Clinic Laboratories.
• AI reaches the bedside. Bayesian Health's sepsis early-warning system was cleared by the FDA and won a Medicare new-technology add-on payment.

Company Analysis: who is positioned, who is exposed

• bioMérieux, Waters (formerly BD Diagnostic Solutions) and Bruker: Own the microbiology workflow, from blood culture to identification and susceptibility testing.
• Roche, Abbott, Siemens Healthineers, Beckman Coulter, Radiometer and Thermo Fisher: Core laboratory and acute-care suppliers of procalcitonin, lactate and other sepsis biomarkers.
• Qiagen, Cepheid and DiaSorin: Molecular blood culture identification panels, with Qiagen completing its US panel set in 2026.
• Inflammatix, Cytovale, Immunexpress and MeMed: Host-response tests that must still win over guideline writers.
• Karius, Q-linea, Gradientech, Scanogen, Bayesian Health and Prenosis: Innovators in sequencing, rapid susceptibility and AI.
• Mindray, Snibe, Autobio, Zhuhai DL Biotech, Getein and Wondfo: Chinese suppliers of blood culture, susceptibility and biomarker tests, growing in their home market.

In all, 38 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Questions this report answers

• How large is the sepsis diagnostics market, and which technologies take the growth?
• How fast will rapid susceptibility, direct-from-blood and host-response tests displace the culture-based workflow?
• What do SEP-1, the new sepsis readmission measure and the 2026 guidelines mean for hospital buying?
• Which care settings grow fastest, from the emergency department to neonatal intensive care?
• Who is gaining after Waters' purchase of BD diagnostics and the exits of T2 Biosystems and Accelerate?
• How large is each country market, and where is growth fastest?

What's inside

• 283 pages, 23 chapters, 61 tables and 49 figures
• Forecasts for 2027–2031 from a 2026 base year, by technology, clinical use, infection source, care setting and product, for 14 countries and regions
• Blood culture and pathogen identification, rapid susceptibility testing and stewardship, biomarkers and host response, and direct-from-blood molecular and sequencing tests
• Care settings, software and AI early warning, regulation, reimbursement and policy, and China, Asia-Pacific and emerging markets
• 10 market-moving developments from 2025 and 2026, SWOT, Porter's Five Forces and strategic recommendations
• 38 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Diagnostic companies and business development teams: plan products for faster sepsis answers, from the emergency department to the microbiology lab.
• Laboratory and health-system leaders: plan microbiology automation, rapid testing and stewardship under new payment rules.
• Investors and analysts: model a fast-growing market after a year of consolidation and failures.
• Public health and AMR programmes: plan sepsis and antimicrobial resistance strategies.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.Sc., M.B.A., is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.